United Health Products, Inc.

United Health Products, Inc. develops and markets patented hemostatic gauze products for wound care and surgical bleeding control. The company is based in the United States and operates through its CelluSTAT product line and related branded formats, with manufacturing and packaging performed through contract and service providers.

0.03

0.03

— United Health Products, Inc.
%
Hemostatic gauze70% Cotton-based gauze designed to absorb drainage and help control bleeding.
Wound care dressings20% Superficial wound and external bleeding products used in healthcare settings.
Branded surgical/wound formats10% Product formats and trademarks associated with the company’s gauze platform.

The company’s target customers are healthcare providers that need products for bleeding control and wound management,...

  • Hospitals and surgery centersprimary

    Buy hemostatic gauze for internal surgical bleeding control and procedural use.

  • Clinics and physicianssecondary

    Use the products for superficial wounds, drainage absorption, and external bleeding.

  • Medical technology partnersprimary

    May commercialize, distribute, or acquire the product platform.

  • Surgical device and wound care companiesprimary

    Potential channel partners or strategic buyers for the product line.

The company is based in the United States, where its products are cut, packaged, and sterilized by service providers...

  • •United States is the core operating and manufacturing base
  • •Cutting, packaging, and sterilization are performed in the U.S.
  • •Commercial opportunity is framed around U.S. and international surgery markets
  • •No country-level revenue disclosure was provided in the excerpts
  • •Geographic exposure is tied to FDA approval and market access

The company is focused on obtaining FDA pre-market approval for its CelluSTAT hemostatic gauze so it can address...

01
Obtain FDA PMA for CelluSTATshort-term

Regulatory approval is the key gate to the company’s intended surgical market expansion.

02
Secure commercialization partnershort-term

A partner can provide distribution, market access, and execution capacity.

03
Maximize value through strategic transactionmedium-term

Management has indicated a sale or merger may be the preferred long-term path.

The company faces substantial regulatory risk because its core growth plan depends on FDA PMA approval, which cannot be...

critical

FDA PMA not granted

The company’s surgical market strategy depends on approval for Class III use.

Scope
CelluSTAT and the Class III surgical market
Materiality
high
critical

Going-concern and liquidity constraints

The company has not yet reached operating scale sufficient to fund overhead internally.

Scope
Corporate funding and development operations
Materiality
high
high

Dilution from equity financing

Future capital raises may be needed to fund regulatory and commercialization efforts.

Scope
Common stock issuance and convertible financing
Materiality
high
high

Commercial execution dependence on partners

The company does not intend to fully commercialize independently.

Scope
Distribution, sales, and market access
Materiality
medium
medium

Competition in hemostatic and surgical device markets

Established competitors may have stronger regulatory, sales, and hospital relationships.

Scope
Wound care and surgical hemostats
Materiality
medium
Stock-based compensation
Operating expenses and equity dilution
Going-concern assessment
Disclosure risk and financial statement presentation
Fair value of financing instruments
Liabilities, equity, and financing costs

Celularity Inc

CELU · Pharmaceutical Preparations

UNITEDHEALTH GROUP INC

UNH · Hospital & Medical Service Plans

UNIVERSAL HEALTH SERVICES INC

UHS · Services-General Medical & Surgical Hospitals, NEC

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

Sanara MedTech Inc.

SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Humacyte, Inc.

HUMA · Biological Products, (No Diagnostic Substances)

: 29/04/2026